Cloning And Mutagenesis Market Size, Share, and Trends 2024 to 2034

The global cloning and mutagenesis market size was USD 3.53 billion in 2023, estimated at USD 4.21 billion in 2024 and is anticipated to reach around USD 22.27 billion by 2034, expanding at a CAGR of 18.12% from 2024 to 2034.

  • Last Updated : August 2024
  • Report Code : 2851
  • Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Cloning and Mutagenesis Market 

5.1. COVID-19 Landscape: Cloning and Mutagenesis Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Cloning and Mutagenesis Market, By Product

8.1. Cloning and Mutagenesis Market, by Product, 2024-2034

8.1.1 Cloning Kits

8.1.1.1. Market Revenue and Forecast (2021-2034)

8.1.2. Mutagenesis Kits

8.1.2.1. Market Revenue and Forecast (2021-2034)

8.1.3. Others

8.1.3.1. Market Revenue and Forecast (2021-2034)

Chapter 9. Global Cloning and Mutagenesis Market, By Technology

9.1. Cloning and Mutagenesis Market, by Technology, 2024-2034

9.1.1. Topo PCR Cloning

9.1.1.1. Market Revenue and Forecast (2021-2034)

9.1.2. Blunt End Cloning

9.1.2.1. Market Revenue and Forecast (2021-2034)

9.1.3. Seamless Cloning

9.1.3.1. Market Revenue and Forecast (2021-2034)

9.1.4. Site-directed Mutagenesis

9.1.4.1. Market Revenue and Forecast (2021-2034)

9.1.5. Others

9.1.5.1. Market Revenue and Forecast (2021-2034)

Chapter 10. Global Cloning and Mutagenesis Market, By End-User 

10.1. Cloning and Mutagenesis Market, by End-User, 2024-2034

10.1.1. Biopharmaceutical & Pharmaceutical Companies

10.1.1.1. Market Revenue and Forecast (2021-2034)

10.1.2. CROs & CMOs

10.1.2.1. Market Revenue and Forecast (2021-2034)

10.1.3. Academic & Research Institutes

10.1.3.1. Market Revenue and Forecast (2021-2034)

Chapter 11. Global Cloning and Mutagenesis Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Product (2021-2034)

11.1.2. Market Revenue and Forecast, by Technology (2021-2034)

11.1.3. Market Revenue and Forecast, by End-User (2021-2034)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Product (2021-2034)

11.1.4.2. Market Revenue and Forecast, by Technology (2021-2034)

11.1.4.3. Market Revenue and Forecast, by End-User (2021-2034)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Product (2021-2034)

11.1.5.2. Market Revenue and Forecast, by Technology (2021-2034)

11.1.5.3. Market Revenue and Forecast, by End-User (2021-2034)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Product (2021-2034)

11.2.2. Market Revenue and Forecast, by Technology (2021-2034)

11.2.3. Market Revenue and Forecast, by End-User (2021-2034)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Product (2021-2034)

11.2.4.2. Market Revenue and Forecast, by Technology (2021-2034)

11.2.4.3. Market Revenue and Forecast, by End-User (2021-2034)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Product (2021-2034)

11.2.5.2. Market Revenue and Forecast, by Technology (2021-2034)

11.2.5.3. Market Revenue and Forecast, by End-User (2021-2034)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Product (2021-2034)

11.2.6.2. Market Revenue and Forecast, by Technology (2021-2034)

11.2.6.3. Market Revenue and Forecast, by End-User (2021-2034)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Product (2021-2034)

11.2.7.2. Market Revenue and Forecast, by Technology (2021-2034)

11.2.7.3. Market Revenue and Forecast, by End-User (2021-2034)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Product (2021-2034)

11.3.2. Market Revenue and Forecast, by Technology (2021-2034)

11.3.3. Market Revenue and Forecast, by End-User (2021-2034)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Product (2021-2034)

11.3.4.2. Market Revenue and Forecast, by Technology (2021-2034)

11.3.4.3. Market Revenue and Forecast, by End-User (2021-2034)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Product (2021-2034)

11.3.5.2. Market Revenue and Forecast, by Technology (2021-2034)

11.3.5.3. Market Revenue and Forecast, by End-User (2021-2034)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Product (2021-2034)

11.3.6.2. Market Revenue and Forecast, by Technology (2021-2034)

11.3.6.3. Market Revenue and Forecast, by End-User (2021-2034)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Product (2021-2034)

11.3.7.2. Market Revenue and Forecast, by Technology (2021-2034)

11.3.7.3. Market Revenue and Forecast, by End-User (2021-2034)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Product (2021-2034)

11.4.2. Market Revenue and Forecast, by Technology (2021-2034)

11.4.3. Market Revenue and Forecast, by End-User (2021-2034)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Product (2021-2034)

11.4.4.2. Market Revenue and Forecast, by Technology (2021-2034)

11.4.4.3. Market Revenue and Forecast, by End-User (2021-2034)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Product (2021-2034)

11.4.5.2. Market Revenue and Forecast, by Technology (2021-2034)

11.4.5.3. Market Revenue and Forecast, by End-User (2021-2034)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Product (2021-2034)

11.4.6.2. Market Revenue and Forecast, by Technology (2021-2034)

11.4.6.3. Market Revenue and Forecast, by End-User (2021-2034)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Product (2021-2034)

11.4.7.2. Market Revenue and Forecast, by Technology (2021-2034)

11.4.7.3. Market Revenue and Forecast, by End-User (2021-2034)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Product (2021-2034)

11.5.2. Market Revenue and Forecast, by Technology (2021-2034)

11.5.3. Market Revenue and Forecast, by End-User (2021-2034)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Product (2021-2034)

11.5.4.2. Market Revenue and Forecast, by Technology (2021-2034)

11.5.4.3. Market Revenue and Forecast, by End-User (2021-2034)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Product (2021-2034)

11.5.5.2. Market Revenue and Forecast, by Technology (2021-2034)

11.5.5.3. Market Revenue and Forecast, by End-User (2021-2034)

Chapter 12. Company Profiles

12.1. Thermo Fisher Scientific, Inc.

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Agilent Technologies, Inc.

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. New England Biolabs

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Merck KGaA

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Takara Bio Inc.

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Promega Corporation

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Bio-Rad Laboratories, Inc.

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Jena Bioscience GmbH

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Danaher

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Assay Genie

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

 

14.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The global cloning and mutagenesis market size is expected to increase USD 22.27 billion by 2034 from USD 3.53 billion in 2023.

The global cloning and mutagenesis market will register growth rate of 18.12% between 2024 and 2034.

The major players operating in the cloning and mutagenesis market are Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., New England Biolabs, Merck KGaA, Takara Bio Inc., Promega Corporation, Bio-Rad Laboratories, Inc., Jena Bioscience GmbH, Danaher, Assay Genie, TransGen Biotech Co., Ltd. and Others.

The driving factors of the cloning and mutagenesis market are the increasing chronic disease across the globe, increasing innovative product launches in cloning and mutagenesis, Increasing research and development investment, and the growing COPD across the globe.

North America region will lead the global cloning and mutagenesis market during the forecast period 2024 to 2034.

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client